Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)

NCT05334368 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05334368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05334368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 6, 2022
Completion date
October 29, 2027
Enrollment
110 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

hypereosinophilic syndrome